entertainment -WSS

entertainment

author：explore 2025-10-08 15:28:10 - browse：8164

A person uses continuous glucose remote monitor with his phone — health tech coverage from STAT — Adobe

A diabetes diagnosis was not what Jason had in mind when he set out on a cross-country road trip with his family in the fall of 2021. He had been heavy since he was a kid, but he always had felt pretty healthy — until getting home to the San Francisco Bay Area, when he started to notice his body doing strange things.

“It kind of came out of nowhere,” said Jason, who asked to keep his last name private. All of a sudden, he had to get up to pee five times in a night. Just a few weeks after his trip, he was having a hard time walking around the block. He went to get checked out at the Palo Alto Medical Foundation, and on a Thursday night in November, the blood test results popped up in his patient portal: He had type 2 diabetes.

“I was freaked out,” he said. “I was in legitimately bad shape.” It would take months to see an endocrinologist. So that day, he signed up to try a novel, telehealth-based approach for managing diabetes with a young company called Steady Health. Jason knew the company through his Bay Area startup connections — as well as Carbon Health, the primary care startup, reportedly valued at more than $3 billion, that had recently acquired Steady.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： AI can decode, harness the power of the humane immune system

focus

hotspot

WSS

Chan Zuckerberg Biohub Chicago to focus on inflammation

PBM executives asked to testify by House panel

Can gargling with Listerine treat gonorrhea of the mouth?

Liquid biopsy for lung cancer is launched by Delfi

FDA rejects Alnylam's heart disease treatment over insufficient data

3 questions for the future of Biden's cancer moonshot

leisure time

entertainment

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Histogen: Failed biotech offers rare public look inside

Moonlake's readout produced a cash windfall. Risks remain

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Virginia high school admissions case could be legal follow

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Sports medicine is finally prioritizing gender equality

Histogen: Failed biotech offers rare public look inside

At least 13 dead in Texas as scorching temps continue

Chemotherapy drug shortage eases slightly but still widespread

entertainment

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

VC firm General Catalyst wants to buy a health system

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

The future of health care in the House

The creative science of coining drug names

Bill would stop addiction treatment from triggering child abuse inquiry

focus

focus

hotspot

explore